Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers.
Joseph StavasArnold L SilvaThomas D WooldridgeAhmed AqeelTheodore SaadRachita PrakashGeorge BakrisPublished in: American journal of nephrology (2024)
The trial is fully enrolled with fifty-three participants. Cell injections and follow-up clinical visits are ongoing. This multicenter phase 2 RCT is designed to investigate the efficacy and safety of rilparencel with bilateral kidney dosing and compare two injection schedules with the potential of preserving or improving kidney function and delaying kidney disease progression among patients with stages 3a-4 CKD with diabetes.
Keyphrases
- cell therapy
- chronic kidney disease
- type diabetes
- stem cells
- end stage renal disease
- mesenchymal stem cells
- glycemic control
- cardiovascular disease
- study protocol
- case report
- phase iii
- platelet rich plasma
- bone marrow
- insulin resistance
- randomized controlled trial
- single cell
- cross sectional
- phase ii
- adipose tissue
- skeletal muscle
- metabolic syndrome
- climate change
- weight loss